The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced that it has recently established the COVID-19 Prevention Network (CoVPN). Its goal is to register millions of volunteers for large-scale clinical testing of vaccines and monoclonal antibodies intended to protect people from COVID-19.
As part of this initiative, Oracle developed a Cloud System called the CoVPN Volunteer Screening Registry to identify and screen volunteers who want to participate in COVID-19 clinical trials. Even though the system has been live for less than a week, more than 100,000 people have already registered.
This program is expected to support hundreds of clinical trial sites across the United States and internationally by the end of the year. The trials are inclusive of absolutely everyone from all communities, with a focus on those who are at higher risk for COVID-19.
“We encourage you to visit the CoVPN website, learn more about the vaccine trial program, and volunteer if you are able at http://covpn.oracle.com/survey,” Oracle said in its press statement.
The CoVPN Volunteer Screening Registry in the latest in a series of COVID-19 cloud application systems built by Oracle to support the U.S. Department of Health and Human Services (HHS), healthcare providers and medical researchers. Taken together, these systems are designed to enable health professionals to collect and analyze the data necessary to better understand and combat COVID-19.
In April, Oracle developed a Therapeutic Learning System (TLS) that allows physicians and patients to record responses to promising COVID-19 drug therapies. With today’s announcement, Oracle is expanding its cooperation with HHS to support the large-scale clinical trials required in the race for a vaccine.
